Similar Papers

Paper Title
Journal
Date
Author
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
Giorgio Scagliotti ... Eun Kyung Cho
Journal of Thoracic Oncology | VOL. 15
Giorgio Scagliotti, et. al.Giorgio Scagliotti ... Eun Kyung Cho
14 Oct 2019
Phase I Study of Apatinib in Combination with Gefitinib As First-Line Treatment in Patients with EGFR-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer
Zhonghan Zhang ... Shaodong Hong
SSRN Electronic Journal | VOL. -
Zhonghan Zhang, et. al.Zhonghan Zhang ... Shaodong Hong
16 Sep 2019
Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Jason S Agulnik ... David Small
Current Oncology | VOL. 28
Jason S Agulnik, et. al.Jason S Agulnik ... David Small
07 Dec 2021
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo ...
Journal of Thoracic Oncology | VOL. 17
Maria Carmela Piccirillo, et. al.Maria Carmela Piccirillo ...
01 Jun 2022
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Board of Directors
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.